Ionis on Thursday said the FDA green light covers Dawnzera for prophylaxis to prevent attacks of hereditary angioedema in patients 12 years of age and older and makes the drug is the first and only ...

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition, and the second wholly owned medicine Ionis has brought to market.

Researchers have discovered that a virus living inside the fungus Aspergillus fumigatus significantly boosts the fungus's ability to survive stress and cause severe infections in mammals. Removing the ...